Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer.
Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer.
复制标题
DOI：
10.4103/aja.aja_58_21
复制
发表时间：
2022-01
影响因子：
2.9
通讯作者：
Toren P
中科院分区：
文献类型：
--
作者：
Kourbanhoussen K;Joncas FH;D Wallis CJ;Hovington H;Dagenais F;Fradet Y;Guillemette C;Lacombe L;Toren P
先前的研究表明，卵泡刺激素（FSH）的循环水平与前列腺癌的预后有关。FSH水平也可以解释一些观察到的使用促性腺激素释放激素（GnRH）拮抗剂与GnRH激动剂治疗的男性心血管事件的差异。本研究评估了在根治性前列腺切除术后长期随访的男性队列中术前FSH与长期心血管和肿瘤预后之间的关系。我们利用机构生物库进行了一项队列研究，并附有注释的临床数据。从冷冻保存的血浆中测量FSH水平，并与先前从相同样本中测量的性类固醇进行比较。采用调整后的cox回归模型比较各组间FSH水平的肿瘤预后差异。主要不良心血管事件（MACE）同样采用住院诊断代码进行评估。共纳入492例患者，中位随访时间为13.1年（四分位数间距：8.9-15.9）。经线性回归分析，脱氢表雄酮硫酸酯（DHEA-S）水平与FSH水平呈负相关，其他雄激素水平与FSH水平呈负相关（P = 0.03）。FSH水平与生化复发、发生去势抵抗性前列腺癌的时间或转移的时间没有关联。50例（10.2%）患者发现mace，平均首次发病时间为8.8年。未发现FSH不育与MACE的发生有关联。我们的研究结果并不表明术前FSH水平与根治性前列腺切除术后前列腺癌患者的肿瘤预后显著相关，这些水平似乎也不是长期心血管风险的预测指标。
Prior research suggests a link between circulating levels of follicle-stimulating hormone (FSH) and prostate cancer outcomes. FSH levels may also explain some of the observed differences in cardiovascular events among men treated with gonadotropin-releasing hormone (GnRH) antagonists compared to GnRH agonists. This study evaluates the association between preoperative FSH and long-term cardiovascular and oncologic outcomes in a cohort of men with long follow-up after radical prostatectomy. We performed a cohort study utilizing an institutional biobank with annotated clinical data. FSH levels were measured from cryopreserved plasma and compared with sex steroids previously measured from the same samples. Differences in oncologic outcomes between tertiles of FSH levels were compared using adjusted cox regression models. Major adverse cardiovascular events (MACE) were similarly assessed using hospital admission diagnostic codes. A total of 492 patients were included, with a median follow-up of 13.1 (interquartile range: 8.9–15.9) years. Dehydroepiandrosterone sulfate (DHEA-S) levels, but not other androgens, negatively correlated with FSH levels on linear regression analysis (P = 0.03). There was no association between FSH tertile and outcomes of biochemical recurrence, time to castrate-resistant prostate cancer, or time to metastasis. MACEs were identified in 50 patients (10.2%), with a mean time to first event of 8.8 years. No association with FSH tertile and occurrence of MACE was identified. Our results do not suggest that preoperative FSH levels are significantly associated with oncologic outcomes among prostate cancer patients treated with radical prostatectomy, nor do these levels appear to be predictors of long-term cardiovascular risk.